Driciru et al. Immunological Considerations for Schistosoma-Vaccine Development
implementation policies. Besides well-designed studies in different target populations using …

Despite mass drug administration programmes with praziquantel, the prevalence of
schistosomiasis remains high. A vaccine is urgently needed to control transmission of this …

Vaccination against human schistosomes in laboratory hosts is now a reality. A number of
different parasite molecules have been shown to confer partial protective immunity against …

Schistosomiasis is a severe parasitic disease, endemic in 74 developing countries with up to
600 million people infected and 800 million, mostly children, at risk of contracting the …

Schistosomiasis is a neglected tropical disease (NTD) of public health importance. Despite
decades of implementation of mass praziquantel therapy programs and other control …

An effective schistosome vaccine is a desirable control tool but progress towards that goal
has been slow. Protective immunity has been difficult to demonstrate in humans, particularly …

The high level of protection elicited in rodents and primates by the radiation-attenuated
schistosome vaccine gives hope that a human vaccine relying on equivalent mechanisms is …

A number of different schistosome antigens are capable of partially protecting experimental
animals from challenge infection. More than 100 such antigens have been identified, about …

Schistosomiasis is a devastating and neglected tropical disease caused by Schistosoma
spp. parasites. The disease remains greatly neglected by global health control programmes …

Schistosomiasis is a parasitic disease caused by helminths belonging to the Schistosoma
genus. Approximately 700 million people are at risk of infection and 200 million people are …